Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gustafsson

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Platelets|July 17, 2013
Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsisMilladur Rahman, David Gustafsson, Yongzhi Wang, et al.
Journal of Medicinal Chemistry|March 26, 2013
Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acidJonas Boström, J Andrew Grant, Ola Fjellström, et al.
Circulation Research|September 18, 2012
Translational success stories: development of direct thrombin inhibitorsMichiel Coppens, John W Eikelboom, David Gustafsson, et al.
Clinical Pharmacokinetics|May 13, 2003
No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteersLinda C Johansson, Magnus Andersson, Gunnar Fager, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophiliaPeter Bach, Laurent Knerr, Ola Fjellström, et al.
Clinical Pharmacokinetics|March 22, 2003
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitorLinda C Johansson, Lars Frison, Ulrika Logren, et al.
Neuroscience Letters|May 15, 2018
Plasminogen binding inhibitors demonstrate unwanted activities on GABA<sub>A</sub> and glycine receptors in human iPSC derived neuronsLisbeth Kristensson, Anders Lundin, David Gustafsson, et al.
Acta Neurochirurgica|December 22, 2021
Prognosis in moderate-severe traumatic brain injury in a Swedish cohort and external validation of the IMPACT modelsElham Rostami, David Gustafsson, Anders Hånell, et al.
Journal of Chemical Information and Modeling|June 28, 2017
Discovery and Evaluation of Anti-Fibrinolytic Plasmin Inhibitors Derived from 5-(4-Piperidyl)isoxazol-3-ol (4-PIOL)Thomas C Schmidt, Per-Olof Eriksson, David Gustafsson, et al.
European Journal of Clinical Pharmacology|May 14, 2003
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjectsUlf G Eriksson, Ulf Bredberg, Kristina Gislén, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Platelets|July 17, 2013
Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsisMilladur Rahman, David Gustafsson, Yongzhi Wang, et al.
Journal of Medicinal Chemistry|March 26, 2013
Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acidJonas Boström, J Andrew Grant, Ola Fjellström, et al.
Circulation Research|September 18, 2012
Translational success stories: development of direct thrombin inhibitorsMichiel Coppens, John W Eikelboom, David Gustafsson, et al.
Clinical Pharmacokinetics|May 13, 2003
No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteersLinda C Johansson, Magnus Andersson, Gunnar Fager, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophiliaPeter Bach, Laurent Knerr, Ola Fjellström, et al.
Clinical Pharmacokinetics|March 22, 2003
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitorLinda C Johansson, Lars Frison, Ulrika Logren, et al.
Neuroscience Letters|May 15, 2018
Plasminogen binding inhibitors demonstrate unwanted activities on GABA<sub>A</sub> and glycine receptors in human iPSC derived neuronsLisbeth Kristensson, Anders Lundin, David Gustafsson, et al.
Acta Neurochirurgica|December 22, 2021
Prognosis in moderate-severe traumatic brain injury in a Swedish cohort and external validation of the IMPACT modelsElham Rostami, David Gustafsson, Anders Hånell, et al.
Journal of Chemical Information and Modeling|June 28, 2017
Discovery and Evaluation of Anti-Fibrinolytic Plasmin Inhibitors Derived from 5-(4-Piperidyl)isoxazol-3-ol (4-PIOL)Thomas C Schmidt, Per-Olof Eriksson, David Gustafsson, et al.
European Journal of Clinical Pharmacology|May 14, 2003
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjectsUlf G Eriksson, Ulf Bredberg, Kristina Gislén, et al.
Pageof 4